Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Monoclonal antibodies as a tool for structure-function studies of the MDR1-P-glycoprotein.

Cianfriglia M, Cenciarelli C, Barca S, Tombesi M, Flego M, Dupuis ML.

Curr Protein Pept Sci. 2002 Oct;3(5):513-30. Review.

PMID:
12369999
2.

Multidrug resistance: molecular mechanisms and clinical relevance.

Ling V.

Cancer Chemother Pharmacol. 1997;40 Suppl:S3-8. Review.

PMID:
9272126
3.
4.
5.

P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.

Breier A, Barancík M, Sulová Z, Uhrík B.

Curr Cancer Drug Targets. 2005 Sep;5(6):457-68. Review.

PMID:
16178819
6.

The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies.

Kuwano M, Uchiumi T, Hayakawa H, Ono M, Wada M, Izumi H, Kohno K.

Cancer Sci. 2003 Jan;94(1):9-14. Review.

7.

Pharmacological strategies for overcoming multidrug resistance.

Nobili S, Landini I, Giglioni B, Mini E.

Curr Drug Targets. 2006 Jul;7(7):861-79. Review.

PMID:
16842217
8.

Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies.

Scheffer GL, Kool M, Heijn M, de Haas M, Pijnenborg AC, Wijnholds J, van Helvoort A, de Jong MC, Hooijberg JH, Mol CA, van der Linden M, de Vree JM, van der Valk P, Elferink RP, Borst P, Scheper RJ.

Cancer Res. 2000 Sep 15;60(18):5269-77.

9.

A new structural model for P-glycoprotein.

Jones PM, George AM.

J Membr Biol. 1998 Nov 15;166(2):133-47.

PMID:
9841738
10.

Search for specific inhibitors of multidrug resistance in cancer.

Sarkadi B, Müller M.

Semin Cancer Biol. 1997 Jun;8(3):171-82. Review.

PMID:
9465371
12.
13.

Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.

Zhou SF.

Xenobiotica. 2008 Jul;38(7-8):802-32. doi: 10.1080/00498250701867889 . Review.

PMID:
18668431
14.
15.

Structural and functional aspects of P-glycoproteins and related transport proteins.

Lepage P, Gros P.

Curr Opin Nephrol Hypertens. 1993 Sep;2(5):735-43. Review.

PMID:
7522912
16.
17.

Recent progress in P-glycoprotein research.

Ueda K, Yoshida A, Amachi T.

Anticancer Drug Des. 1999 Apr;14(2):115-21. Review.

PMID:
10405638
18.

The multidrug resistance P-glycoprotein. Oligomeric state and intramolecular interactions.

Taylor JC, Horvath AR, Higgins CF, Begley GS.

J Biol Chem. 2001 Sep 28;276(39):36075-8. Epub 2001 Aug 8.

19.

The extracellular loop between TM5 and TM6 of P-glycoprotein is required for reactivity with monoclonal antibody UIC2.

Zhou Y, Gottesman MM, Pastan I.

Arch Biochem Biophys. 1999 Jul 1;367(1):74-80.

PMID:
10375401
20.

New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.

Molnar J, Mucsi I, Nacsa J, Hevér A, Gyémánt N, Ugocsai K, Hegyes P, Kiessig S, Gaal D, Lage H, Varga A.

Anticancer Res. 2004 Mar-Apr;24(2B):865-71.

Supplemental Content

Support Center